Deferasirox in the treatment of iron overload during myeloproliferative neoplasms in fibrotic phase: does ferritin decrement matter?

•Iron overload is a major concern in Ph-negative myeloproliferative neoplasms in fibrotic phase.•The clinical use of DFX and its benefit are not consolidated FP-MPN.•A larger cohort of FP-MPN patients with iron overload treated with DFX was analyzed.•A rate of about 40% of global responses in terms of ferritin reduction was observed.•FP-MPN patients reaching a reduction of ferritin had a longer OS compared to patients who failed.